close
Home
COVID-19
chevron_right
#WE-WONT-REST
chevron_right
News & Events
chevron_right
About medicines
chevron_right
Relationships & code
chevron_right
Publications
chevron_right
About us
chevron_right
Contact us
KMS Login
arrow_back
close
COVID-19
Member Updates
News
#WE-WONT-REST
The impact of innovation
expand_more
expand_less
chevron_right
Anti-amyloid therapies to treat Alzheimer’s Disease
Car-T therapies
Combination therapies for lung cancer
Anti-viral therapies for Hepatitis B and HIV
Gene therapies for rare diseases
mRNA vaccines for brain cancer
Remyelinating therapies for e.g. Multiple sclerosis
NASH treatments
Patient stories
expand_more
expand_less
chevron_right
Alzheimer's patient story
Blood cancer patient story
Lung cancer patient story
Haemophilia patient story
Pledge Wall
Members updates
Questions Inspire Solutions
News & Events
The EFPIA View
Events
Newsletter
About medicines
Development of medicines
expand_more
expand_less
chevron_right
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Use of medicines
expand_more
expand_less
chevron_right
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
expand_more
expand_less
chevron_right
Back Innovation, Boost Access
Relationships & code
The EFPIA Code
Patient organisations
Healthcare professionals (HCPs)
Disclosure of payments to HCPs
National codes
EU institutions
Publications
Data center
Downloads
Cancer Comparator Report
expand_more
expand_less
chevron_right
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
About us
Who we are
EFPIA Japan
Membership
Job vacancies
Contact us
arrow_back
close
The impact of innovation
Anti-amyloid therapies to treat Alzheimer’s Disease
Car-T therapies
Combination therapies for lung cancer
Anti-viral therapies for Hepatitis B and HIV
Gene therapies for rare diseases
mRNA vaccines for brain cancer
Remyelinating therapies for e.g. Multiple sclerosis
NASH treatments
Development of medicines
Animal Use and Welfare
Antimicrobial resistance (AMR)
Digital Health
Intellectual Property
Precision medicine
Public-private partnerships
Regulations, safety & supply
SMEs in Europe
Trade
Use of medicines
HTA & Relative Efficacy Assessment
Disease-specific groups
Healthcare Systems
Value of medicines
Access to medicines
Back Innovation, Boost Access
Cancer Comparator Report
About
Recommendations
Cancer Cases
Cancer Deaths
Survival
Cancer Care
Cancer Types
Resources
News & Events
The EFPIA view
Podcast: How can...
Podcast: How can we keep SMEs in Europe?
close
Podcast: How can we keep SMEs in Europe?
Welcome to 19 conversations
apps
The EFPIA View
chevron_left
Previous
print
Print
Next
chevron_right
Podcast: How can we keep SMEs in Europe?
05.11.20
Today we're asking Erik van den Berg, Chief Executive Officer, AM Pharma: How can we keep SMEs in Europe?
Listen to hear their discussion on the challenge and how we're preparing for the future.
close
continue
/